Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Implementing International Standards of Practice in A Low Resource Country by Blended Training Modules to Improve Stroke Care

2. August 2021 aktualisiert von: Foundation University Islamabad
Lack of proper stroke care delivery leads to poor patient outcomes in middle- and low-income countries that can be improved by implementation of international standards. We aim to determine feasibility of implementing stroke core measures and training through blended learning modules in resource poor countries to improve stroke outcomes.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Detaillierte Beschreibung

Background: Lack of proper stroke care delivery leads to poor patient outcomes in middle- and low-income countries that can be improved by implementation of international standards. We aim to determine feasibility of implementing stroke core measures and training through blended learning modules in resource poor countries to improve stroke outcomes.

Methods: The project will be conducted across four hospitals in Pakistan in three phases. First stage will include retrospective collection of data for the preceding 4 weeks from start. In stage II, 3 months data will be collected before implementation of core measures. The stepwise training of staff will begin simultaneously, and data will continue to be collected. In stage III by the end of 3 months of stage II, core measures will be implemented as standard of care and patients will be enrolled for another 3 months. Outcomes measures will be successful implementation of the stroke care model as measured by survey done at the end and patient outcomes including in-hospital complication rates, length of hospital stay, patient and caregiver education, mRS at 3 months after discharge, post discharge complications and re-stroke rate. Data will be compared against published data from Pakistan and between patients in the first and last 3 months of the project. Statistical analyses will include appropriate mixed-effects multivariate regression models (i.e., linear and logistic) to model the relationship between clinical measures and patient safety. Degree of correlation across each symptom predictor will be measured. This study will not involve thrombolytic therapy or thrombectomy. However, the study will not provide any hindrance to implementation of such therapy and will not include such patients in analysis.

Discussion: At least one third of stroke survivors in Pakistan die due to recurrent vascular events and complications of stroke in absence of core measures. Prevention practices and stroke care are significantly underutilized in low- and middle-income countries but can be improved most efficiently by improving care delivering process without additional burden on resources by following American Heart Association "Get With The Guidelines" Stroke (GWTG-Stroke) program, Royal College of Physicians UK and European Guidelines, regardless of thrombolysis or thrombectomy. This feasibility study aims to develop a multidisciplinary comprehensive stroke team model with gradual integration of staff training, nursing care, therapy and patient education.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

100

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Punjab
      • Rawalpindi, Punjab, Pakistan, 46000
        • Fauji Foundation Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients presenting with acute stroke symptoms as deemed by treating physicians presenting to the ED will be enrolled. Normative data from the general population will be used where needed for comparison.

Beschreibung

Inclusion Criteria:

Acute onset of Symptoms in the last 24 hours suggestive of stroke Age > 18 years Ischemic or hemorrhagic stroke

-

Exclusion Criteria:

Presenting after 24 hours of onset of symptoms Alternate explanation for presenting symptoms (stroke mimics) Family (Surrogate Decision Maker) or next of kin/ patient refusal for participation Transfer of care from another department or hospital Care needed in another department (e.g, ICU, other department) GCS (Glasgow Coma Scale) below 5 or End of life care initiated TIA (Transient Ischemic Attack)

-

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Retrospective 3 months cohort (admitted stroke patients)
  1. Extracranial imaging
  2. ECG in 2-7 days
  3. DVT prophylaxis
  4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management
  5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent
  6. Fasting lipid profile, HbA1c
  7. Holter monitor
  8. Specialized workup for young stroke
  9. PFO Study, MES Study
  10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team
  11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography
  12. Follow-up plan and 90 day mRS
Prospective pre-implementation "standard of core care quality measures" cohort
  1. Extracranial imaging
  2. ECG in 2-7 days
  3. DVT prophylaxis
  4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management
  5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent
  6. Fasting lipid profile, HbA1c
  7. Holter monitor
  8. Specialized workup for young stroke
  9. PFO Study, MES Study
  10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team
  11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography
  12. Follow-up plan and 90 day mRS
Prospective post-implementation "standard of core care quality measures" cohort
  1. Extracranial imaging
  2. ECG in 2-7 days
  3. DVT prophylaxis
  4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management
  5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent
  6. Fasting lipid profile, HbA1c
  7. Holter monitor
  8. Specialized workup for young stroke
  9. PFO Study, MES Study
  10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team
  11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography
  12. Follow-up plan and 90 day mRS

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Post Core Measure Delivery
Zeitfenster: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
• Primary outcome measure will be successful implementation of the stroke care model as measured by survey done at the end assessing engagement and ability to continue the program in future and ability to implement the program across institutions. This will be measured by the NIHSS training, stroke education, awareness of core measures, the regularity of following the core measure and data collection.
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Modified Rankin Scale
Zeitfenster: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
Modified Rankin Scale is a 6 point disability scale from 0-6, and a greater score means worse outcome.
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
New ischemic stroke or Transient Ischemic Attack:
Zeitfenster: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
Hemorrhagic transformation:
Zeitfenster: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
Intracranial hemorrhage:
Zeitfenster: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 days
Death
Zeitfenster: From date of inclusion in the study until the date of discharge
From date of inclusion in the study until the date of discharge

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Januar 2021

Primärer Abschluss (Tatsächlich)

30. Juni 2021

Studienabschluss (Voraussichtlich)

31. Dezember 2021

Studienanmeldedaten

Zuerst eingereicht

13. Februar 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. August 2021

Zuerst gepostet (Tatsächlich)

6. August 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. August 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. August 2021

Zuletzt verifiziert

1. April 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Clinical stroke extended management pathway

3
Abonnieren